Relypsa, Inc. is a privately held biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform. To date, Relypsa has raised $33 million in Series A financing. Investors include 5AM Ventures, New Leaf Venture Partners, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners.